- Evolus Announces Appointment of Albert G. White III to Board of Directors
- Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products
- Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain
- Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting
- Evolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau® at the Women’s Wear Daily Beauty CEO Summit
- Evolus’ Sandra Beaver Named Orange County Business Journal’s Public Company CFO of the Year
- Evolus Reports First Quarter 2024 Results and Provides Business Update
- Evolus to Report First Quarter Financial Results on May 7, 2024
More ▼
Key statistics
On Tuesday, Evolus Inc (EOLS:NMQ) closed at 12.03, -22.05% below its 52-week high of 15.43, set on Mar 04, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 12.15 |
---|---|
High | 12.41 |
Low | 12.00 |
Bid | 11.70 |
Offer | 12.49 |
Previous close | 12.07 |
Average volume | 336.86k |
---|---|
Shares outstanding | 62.61m |
Free float | 48.91m |
P/E (TTM) | -- |
Market cap | 755.71m USD |
EPS (TTM) | -1.05 USD |
Data delayed at least 15 minutes, as of Jul 16 2024 20:59 BST.
More ▼